TY - JOUR
T1 - End-therapy positron emission tomography for treatment response assessment in follicular lymphoma
T2 - A systematic review and meta-analysis
AU - Pyo, Junhee
AU - Kim, Kyung Won
AU - Jacene, Heather A.
AU - Sakellis, Christopher G.
AU - Brown, Jennifer R.
AU - Van Den Abbeele, Annick D.
AU - Behrens, C.
PY - 2013/12/1
Y1 - 2013/12/1
N2 - Purpose: Use of 2[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in postchemotherapy response assessment in follicular lymphoma is stilla controversial issue. Here, we conducted the first systematic review and meta-analysis to determine the predictive value of FDG-PET in predicting outcome after chemotherapy of follicular lymphoma. Experimental Design: Comprehensive literature search in Ovid-MEDLINE and EMBASE databases was performed to identify studies which evaluate predictive value of end-therapy PET and/or computed tomography (CT) in patients with follicular lymphoma. To quantitatively compare the predictive value of PET and CT, pooled hazard ratios (HRs) comparing progression-free survival (PFS) between patients with positive and negative results were adopted as the primary indicators for meta-analysis. To explore the efficiency in determining complete remission (CR), pooled CR rates of PET- and CT-based response criteria were calculated. Pooling of these parameters was based on the random-effects model. Results: Review of 285 candidate articles identified eight eligible articles with a total of 577 patients for qualitative review and meta-analysis. The pooled HRs of end-therapy PET and CT were 5.1 [95% confidence interval (CI), 3.7-7.2] and 2.6 (95% CI, 1.2-5.8), respectively, which implies that PET is more predictive of PFS after chemotherapy than CT. The pooled CR rates of PET- and CT-based response criteria were 75% (95% CI, 70-79%) and 63% (95% CI, 53-73%), respectively, which implies that PET is more efficient in distinguishing CR (without residual disease) from other states with residual disease. In addition, qualitative systematic review indicates the same findings. Conclusions: Consistent evidence favoring PET-based treatment assessment should be consideredinthe management of patients with follicular lymphoma.
AB - Purpose: Use of 2[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in postchemotherapy response assessment in follicular lymphoma is stilla controversial issue. Here, we conducted the first systematic review and meta-analysis to determine the predictive value of FDG-PET in predicting outcome after chemotherapy of follicular lymphoma. Experimental Design: Comprehensive literature search in Ovid-MEDLINE and EMBASE databases was performed to identify studies which evaluate predictive value of end-therapy PET and/or computed tomography (CT) in patients with follicular lymphoma. To quantitatively compare the predictive value of PET and CT, pooled hazard ratios (HRs) comparing progression-free survival (PFS) between patients with positive and negative results were adopted as the primary indicators for meta-analysis. To explore the efficiency in determining complete remission (CR), pooled CR rates of PET- and CT-based response criteria were calculated. Pooling of these parameters was based on the random-effects model. Results: Review of 285 candidate articles identified eight eligible articles with a total of 577 patients for qualitative review and meta-analysis. The pooled HRs of end-therapy PET and CT were 5.1 [95% confidence interval (CI), 3.7-7.2] and 2.6 (95% CI, 1.2-5.8), respectively, which implies that PET is more predictive of PFS after chemotherapy than CT. The pooled CR rates of PET- and CT-based response criteria were 75% (95% CI, 70-79%) and 63% (95% CI, 53-73%), respectively, which implies that PET is more efficient in distinguishing CR (without residual disease) from other states with residual disease. In addition, qualitative systematic review indicates the same findings. Conclusions: Consistent evidence favoring PET-based treatment assessment should be consideredinthe management of patients with follicular lymphoma.
UR - http://www.scopus.com/inward/record.url?scp=84890264983&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890264983&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-13-1511
DO - 10.1158/1078-0432.CCR-13-1511
M3 - Review article
C2 - 24052020
AN - SCOPUS:84890264983
SN - 1078-0432
VL - 19
SP - 6566
EP - 6577
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 23
ER -